Oppenheimer Asset Management Inc. boosted its stake in shares of Bruker Co. (NASDAQ:BRKR – Free Report) by 8.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,859 shares of the medical research company’s stock after acquiring an additional 1,756 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Bruker were worth $1,362,000 as of its most recent SEC filing.
Other hedge funds have also recently bought and sold shares of the company. Congress Asset Management Co. MA bought a new stake in shares of Bruker during the second quarter worth $95,159,000. Norges Bank bought a new stake in shares of Bruker during the fourth quarter worth $76,958,000. Goldman Sachs Group Inc. grew its holdings in shares of Bruker by 84.2% during the second quarter. Goldman Sachs Group Inc. now owns 1,553,932 shares of the medical research company’s stock worth $114,867,000 after purchasing an additional 710,228 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Bruker by 4.5% during the first quarter. Vanguard Group Inc. now owns 11,253,314 shares of the medical research company’s stock worth $723,588,000 after purchasing an additional 487,688 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Bruker by 4,042.9% during the third quarter. Assenagon Asset Management S.A. now owns 320,166 shares of the medical research company’s stock worth $19,946,000 after purchasing an additional 312,438 shares during the last quarter. 79.78% of the stock is currently owned by institutional investors and hedge funds.
Bruker Stock Down 4.3 %
BRKR stock opened at $70.70 on Thursday. The company has a quick ratio of 1.04, a current ratio of 1.89 and a debt-to-equity ratio of 0.90. Bruker Co. has a twelve month low of $53.79 and a twelve month high of $84.84. The business has a 50 day moving average price of $71.41 and a two-hundred day moving average price of $66.07. The company has a market cap of $9.79 billion, a price-to-earnings ratio of 32.58, a P/E/G ratio of 2.34 and a beta of 1.14.
Bruker Dividend Announcement
Analyst Ratings Changes
Several brokerages have recently commented on BRKR. Wells Fargo & Company assumed coverage on Bruker in a report on Tuesday, December 19th. They set an “equal weight” rating and a $72.00 target price on the stock. Wolfe Research assumed coverage on Bruker in a report on Wednesday, December 13th. They issued an “outperform” rating and a $80.00 price target on the stock. Finally, JPMorgan Chase & Co. decreased their price target on Bruker from $70.00 to $65.00 and set a “neutral” rating on the stock in a report on Tuesday, October 17th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $80.00.
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies.
- Five stocks we like better than Bruker
- What is Forex and How Does it Work?
- Can Etsy stock craft rebound with support from big investor?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 education stocks breaking out on a hiring spree
- Utilities Stocks Explained – How and Why to Invest in Utilities
- e.l.f. Beauty on a shelf; a good time to buy
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.